Dutch Ophthalmic Research Center (DORC) is a world-leading retinal surgical instrument developer. Even so, CEO Pierre Billardon recognizes the company has a fair percentage of United States market share to obtain.

To take the private equity-backed company through its next growth phase — the goal is to double its equity in three to five years — Pierre listened to DORC’s surgeon customers, strengthened its team, and improved DORC’s internal and external communication.

While innovation remains a key driver for DORC, Pierre remains focused on developing practical solutions. One key example: DORC’s disposable flat vitrectomy lens, a favorite device of host Firas Rahal, MD. 

In this episode, Dr. Rahal speaks with Pierre about the technology behind TissueBlue, the only FDA-approved selective stain for the ILM, and why it’s superior to using ICG off label for ILM staining.

You’ll also discover: 

·         How Pierre’s success at HumanOptics, manufacturer of the CustomFlex artificial iris, has informed his position at DORC. CustomFlex is the first ophthalmic device to receive FDA Breakthrough Device designation.

·         The engineering behind the EVA Phaco-Vitrectomy system and how it brings LED “light to the eye.”

·         How Pierre plans to obtain and maintain market share in a competitive landscape and his vision for the future.

·         Why he considers his current leadership role the “job of his dreams.”

Listen Now !